Auer I O, Habscheid W, Hiller S, Gerhards W, Eilles C
Dtsch Med Wochenschr. 1987 Jun 26;112(26):1032-7. doi: 10.1055/s-2008-1068189.
51Cr-EDTA activity was measured in urine and blood of patients receiving non-steroidal anti-inflammatory (NSA) drug treatment and of healthy subjects and other patients (controls), after oral intake of 51Cr-EDTA, for the purpose of deciding whether NSA treatment increases urinary excretion of oral 51Cr-EDTA as an expression of increased intestinal permeability. 51Cr-EDTA activity in urine and blood of patients with rheumatoid arthritis (13) being treated with NSA was significantly higher (similar to results in 13 patients with Crohn's disease) than that of a control group (14) of patients with rheumatoid arthritis without such treatment (9) and patients without rheumatic disease (5). Both in patients with rheumatoid arthritis receiving NSA drugs and patients with Crohn's disease there was a highly significant correlation between urinary and blood activity. There was no effect of NSA drugs on renal function. The results indicate that NSA drugs increase interenterocytic permeability to an extent comparable to permeability abnormalities in Crohn's disease.
为了确定非甾体抗炎(NSA)药物治疗是否会增加口服51Cr - EDTA的尿排泄量,以此作为肠道通透性增加的一种表现,在口服51Cr - EDTA后,对接受NSA药物治疗的患者以及健康受试者和其他患者(对照组)的尿液和血液中的51Cr - EDTA活性进行了测量。接受NSA治疗的类风湿关节炎患者(13例)尿液和血液中的51Cr - EDTA活性显著高于未接受此类治疗的类风湿关节炎对照组患者(14例,其中类风湿关节炎患者9例,无风湿性疾病患者5例)(类似于13例克罗恩病患者的结果)。接受NSA药物治疗的类风湿关节炎患者和克罗恩病患者的尿液和血液活性之间均存在高度显著的相关性。NSA药物对肾功能没有影响。结果表明,NSA药物会使肠细胞间通透性增加,其程度与克罗恩病中的通透性异常相当。